{
    "clinical_study": {
        "@rank": "48527", 
        "arm_group": [
            {
                "arm_group_label": "paliperidone", 
                "arm_group_type": "Experimental", 
                "description": "paliperidone arm,6mg/pill,6-12mg/day.last12weeks."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo group,6mg/pill,6-12mg/day non-forced titration method,last 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Methamphetamine  substance use is common worldwide. No approved pharmacologic treatments for\n      methamphetamine dependence exist. paliperidone are Second generation antipsychotics\uff0cand have\n      effects of  blocking dopamine2(D2) and 5-hydroxytryptamine 2A(5-HT) receptors\n      neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among\n      methamphetamine addicts."
        }, 
        "brief_title": "An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Methamphetamine Dependence", 
        "detailed_description": {
            "textblock": "Methods:A Multiple-Center, Randomized, Double-Blind."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV)\n             criteria for Methamphetamine dependence.\n\n          2. Must sign a Information consent form.\n\n          3. Required to provide detailed address and phone number\n\n        Exclusion Criteria:\n\n          1. Serious organic disease.\n\n          2. Suicide ideation or hurt others.\n\n          3. Taking antipsychotic within two weeks before.\n\n          4. drug allergy to  Risperidone or paliperidone.\n\n          5. pregnancy and breastfeeding women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825928", 
            "org_study_id": "100000-068944"
        }, 
        "intervention": [
            {
                "arm_group_label": "paliperidone", 
                "description": "Paliperidone  group,6mg/pill,6-12mg/day non-forced titration method,last 12weeks", 
                "intervention_name": "Paliperidone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paliperidone Extended-Release Tablets", 
                    "Invega"
                ]
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "placebo group,6mg/pill,6-12mg/day non-forced titration method,last 12 weeks", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methamphetamine", 
                "9-hydroxy-risperidone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Methamphetamine-Associated Psychosis", 
            "paliperidone"
        ], 
        "lastchanged_date": "April 5, 2013", 
        "location": {
            "contact": {
                "email": "visa8752@yahoo.com.cn", 
                "last_name": "Gang Wang, doctor", 
                "phone": "18684667092"
            }, 
            "facility": {
                "address": {
                    "city": "Changsha", 
                    "country": "China", 
                    "state": "Hunan", 
                    "zip": "410011"
                }, 
                "name": "The Second Xiangya Hospital of Central University"
            }, 
            "investigator": {
                "last_name": "Gang Wang, doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multiple-Center, Randomized, Double-Blind Study of Paliperidone Extended-Release Tablets for Treatment of Methamphetamine Dependence", 
        "overall_contact": {
            "email": "visa8752@yahoo.com.cn", 
            "last_name": "Gang Wang, doctor", 
            "phone": "18684667092"
        }, 
        "overall_official": {
            "affiliation": "Central South University", 
            "last_name": "Wei Hao, MD., Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Ethics Committee", 
                "China: National Natural Science Foundation", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "duration days of methamphetamine-negative urine test results.", 
            "measure": "abstinent time of Methamphetamine addict", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825928"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Central South University", 
            "investigator_full_name": "Wei Hao", 
            "investigator_title": "The Second Xiangya Hospital of Cental South University", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of people who assessed by Abnormal Involuntary Movement Scale ,Simpson-Angus Scale and Barnes akathisia Scale and at least one  scale score is greater than 1.", 
                "measure": "number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "Change in score of Brief Symptom Inventory\uff08BSA\uff09", 
                "measure": "General severity of Methamphetamine addict", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "Change in score of Irritability\uff0cDepression and Anxiety Scale \uff08IDA\uff09", 
                "measure": "Irritability severity of Methamphetamine addict", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }
        ], 
        "source": "Central South University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wei Hao", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}